Original ArticlePancreas, Biliary Tract, and LiverProspective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging–Proton Density Fat Fraction as the Standard
Section snippets
Study Participant and Design
This is a prospective study designed to compare CAP measurement using M vs the XL probe for the detection of hepatic steatosis in participants prospectively recruited and screened for the presence of hepatic steatosis, using MRI-PDFF as reference. All participants underwent MRI-PDFF and CAP measurements using a FibroScan with both M and XL probes. We followed the Standards for Reporting of Diagnostic Accuracy guidelines in this study of CAP in detecting hepatic steatosis (Supplementary Table 1).
Study Participants
A total of 100 participants with or without NAFLD with MRI-PDFF assessment and CAP measurements using both M and XL probes were included in the analysis (Table 1). The majority of the participants (66%) had an MRI and CAP with the M and XL probes the same day and the mean time between MRI and CAP assessment was 11.3 (95% confidence interval [CI], 6.2–16.5) days. Both CAP measurements with the M and XL probes were significantly correlated, with hepatic fat content assessed by MRI-PDFF (
Main Findings
We conducted a prospective study including well-characterized American adults with NAFLD and without NAFLD who underwent CAP measurement using both the M and XL probes for the quantification of liver fat content and MRI-PDFF assessment as the gold standard. We report that CAP measurements using the M probe underestimate the hepatic fat content compared with CAP measurements using the XL probe for the same quantity of MRI-PDFF hepatic fat content, even when the probe is selected according to the
References (29)
- et al.
Sampling variability of liver biopsy in nonalcoholic fatty liver disease
Gastroenterology
(2005) - et al.
The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan
Clin Res Hepatol Gastroenterol
(2012) - et al.
Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease
Gastroenterology
(2019) - et al.
Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter
J Hepatol
(2017) - et al.
Non-invasive evaluation of liver fibrosis using transient elastography
J Hepatol
(2008) - et al.
Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes
Hepatology
(2016) - et al.
Liver biopsy
Hepatology
(2009) - et al.
Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)
Hepatology
(2015) - et al.
Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD
Aliment Pharmacol Ther
(2012) - et al.
Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis
Radiology
(2013)
Hepatic steatosis: quantification by proton density fat fraction with MR imaging versus liver biopsy
Radiology
Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis
Hepatology
Controlled attenuation parameter (CAP) with the XL probe of the Fibroscan(R): a comparative study with the M probe and liver biopsy
Dig Dis Sci
Controlled attenuation parameter using the FibroScan(R) XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population
United Eur Gastroenterol J
Cited by (0)
This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e95. Learning Objective–Upon completion of this activity, successful learners will be able to manage a patient with nonalcoholic fatty liver disease including noninvasive tests for the stage of the disease and treatment.
Conflicts of interest The authors disclose no conflicts.
Funding This work was supported by Atlantic Philanthropies, Inc, the John A. Hartford Foundation, OM, the Association of Specialty Professors, and the American Gastroenterological Association, and National Institutes of Health grant K23-DK090303 (to Rohit Loomba). Rohit Loomba is supported in part by the American Gastroenterological Association Foundation–Sucampo–ASP Designated Research Award in Geriatric Gastroenterology and by a T. Franklin Williams Scholarship Award. The project described and Rohit Loomba were partially supported by National Institute of Environmental Health Sciences grant 5P42ES010337 and National Center for Advancing Translational Sciences grant 5UL1TR001442. Claude B. Sirlin and Rohit Loomba also received support from the National Institute of Diabetes and Digestive and Kidney Diseases grant R01-DK106419. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.